NASDAQ:LYEL Lyell Immunopharma Q3 2026 Earnings Results & Report $15.80 -1.06 (-6.28%) As of 02:11 PM Eastern This is a fair market value price provided by Massive. Learn more. Lyell Immunopharma beat analyst earnings expectations but missed on revenue in its Q3 2026 results, released November 4, 2026. The company reported EPS of -$1.86 versus the -$2.0063 consensus estimate, while revenue of $3 thousand fell short of the $4 thousand estimate by $1 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 4, 2026TimeAfter Market ClosesConference Call7:00 AM ET Lyell Immunopharma EPS ResultsActual EPS-$1.86Consensus EPS -$2.0063Beat/MissBeat by +$0.1463One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersLyell Immunopharma Revenue ResultsActual Revenue$3 thousandExpected Revenue$4 thousandBeat/MissMissed by -$1.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Lyell Immunopharma Q3 2026 Earnings FAQ Did Lyell Immunopharma beat earnings estimates for Q3 2026? Lyell Immunopharma (NASDAQ:LYEL) reported earnings of -$1.86 per share for Q3 2026, beating the consensus estimate of -$2.0063. The report was announced on Wednesday, November 4, 2026. What was Lyell Immunopharma's revenue for Q3 2026? Lyell Immunopharma reported revenue of $3 thousand for Q3 2026, against a consensus estimate of $4 thousand. Lyell Immunopharma Earnings HeadlinesLyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptNovember 11 at 3:17 PM | seekingalpha.comLyell Immunopharma (NASDAQ:LYEL) Major Shareholder Acquires $24,999,991.74 in StockNovember 8, 2026 | americanbankingnews.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 12 at 1:00 AM | Base Camp Trading (Ad)Lyell: Upgrade To 'Buy' On Ronde-Cel Advancement LBCL And $80 Million Funding BoostNovember 5, 2026 | seekingalpha.comLyell Immunopharma (NASDAQ:LYEL) Earns "Buy" Rating from Needham & Company LLCNovember 5, 2026 | americanbankingnews.comLyell Immunopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMSee More Lyell Immunopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lyell Immunopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lyell Immunopharma and other key companies, straight to your email. Email Address About Lyell ImmunopharmaLyell Immunopharma (NASDAQ:LYEL) is a clinical-stage biotechnology company developing engineered T-cell therapies for people with cancer, with a focus on solid tumors. Its research aims to improve T cells’ ability to recognize and attack cancer cells and to remain active in the challenging environment inside tumors. The company’s investigational programs have included CAR T-cell and tumor-infiltrating lymphocyte (TIL) therapies. These approaches use a patient’s own immune cells, which are modified or selected and expanded before being administered as a potential treatment. Lyell’s candidates have been studied in clinical trials for cancers including breast cancer, lung cancer and melanoma; they are investigational and are not approved treatments. Founded in 2018, Lyell is based in South San Francisco, California. Its work centers on research and clinical development, including studies conducted in the United States. The company’s programs and priorities may change as clinical results and development plans evolve.View Lyell Immunopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCoreWeave's Backlog Is Surging—Can the Stock Follow?Can Constellation Energy's Contracts Power a Stock Rebound? Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
